AVTX Insider Trading
Insider Ownership Percentage: 0.25%
Insider Buying (Last 12 Months): $6,250.00
Insider Selling (Last 12 Months): $0.00
Avalo Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Avalo Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Avalo Therapeutics Share Price & Price History
Current Price: $6.85
Price Change: ▼ Price Decrease of -1.16 (-14.48%)
As of 04/1/2025 05:00 PM ET
Avalo Therapeutics Insider Trading History
Avalo Therapeutics Institutional Trading History
Data available starting January 2016
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Read More on Avalo Therapeutics
Volume
28,146 shs
Average Volume
72,146 shs
Market Capitalization
$73.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.86
Who are the company insiders with the largest holdings of Avalo Therapeutics?